{"id":60437,"date":"2026-04-03T07:12:10","date_gmt":"2026-04-03T05:12:10","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/04\/03\/targeting-tlr2-agonists-as-immunomodulators-with-broad-antiviral-activity-nongthombam-boby\/"},"modified":"2026-04-03T07:12:10","modified_gmt":"2026-04-03T05:12:10","slug":"targeting-tlr2-agonists-as-immunomodulators-with-broad-antiviral-activity-nongthombam-boby","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/04\/03\/targeting-tlr2-agonists-as-immunomodulators-with-broad-antiviral-activity-nongthombam-boby\/","title":{"rendered":"Targeting TLR2 agonists as immunomodulators with broad antiviral activity. Nongthombam Boby"},"content":{"rendered":"<div>\n<p><b>Trends Immunol<\/b>. 2026 Apr 1:S1471-4906(26)00062-1. doi: 10.1016\/j.it.2026.03.003. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Toll-like receptor-2 (TLR2) serves as an innate immune sensor that recognizes specific viral proteins, thereby initiating signaling pathways that can either enhance antiviral host defenses or induce pathological inflammatory responses. In this forum, we discuss the role of TLR2 and its agonists in enhancing antiviral and vaccine-induced immune responses.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41927357\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=100966032&amp;ff=20260403011208&amp;v=2.19.0.post6+133c1fe\">41927357<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1016\/j.it.2026.03.003\">10.1016\/j.it.2026.03.003<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Trends Immunol. 2026 Apr 1:S1471-4906(26)00062-1. doi: 10.1016\/j.it.2026.03.003. Online ahead of print. ABSTRACT Toll-like receptor-2 (TLR2) serves as an innate immune sensor that recognizes specific viral proteins, thereby initiating signaling pathways that can either enhance antiviral host defenses or induce pathological inflammatory responses. In this forum, we discuss the role of TLR2 and its agonists in &#8230; <a title=\"Targeting TLR2 agonists as immunomodulators with broad antiviral activity. Nongthombam Boby\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/03\/targeting-tlr2-agonists-as-immunomodulators-with-broad-antiviral-activity-nongthombam-boby\/\" aria-label=\"Read more about Targeting TLR2 agonists as immunomodulators with broad antiviral activity. Nongthombam Boby\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,68],"tags":[],"class_list":["post-60437","post","type-post","status-publish","format-standard","hentry","category-publicaciones","category-trends-in-immunology"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/60437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=60437"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/60437\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=60437"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=60437"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=60437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}